Precigen (PGEN) Notes Payables (2012 - 2023)

Precigen (PGEN) posted quarterly Notes Payables of $13.8 million for Q1 2023, down 68.03% quarter-over-quarter from $43.2 million in Q4 2022.

Analysis

Precigen (PGEN) Notes Payables (2012 - 2023) Analysis & Trends

Precigen (PGEN) has reported Notes Payables for 2 consecutive years, with $13.8 million the latest figure, recorded in Q1 2023.

In Q1 2023, Notes Payables changed N/A year-over-year to $13.8 million; the TTM figure through Mar 2023 stood at $13.8 million (changed N/A YoY), while the FY2022 annual figure was $43.2 million, changed N/A from the prior year.
Notes Payables slipped to $13.8 million in Q1 2023 per PGEN's latest filing, from $43.2 million in the prior quarter.
Across five years, Notes Payables topped out at $43.2 million in Q4 2022 and bottomed at $13.8 million in Q1 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Precigen	2.53 Bn	2.53 Bn	52.17 Mn

Historic Data

Download Data